This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Medicine. This report contains market size and forecasts of Anti-VEGF Medicine in global, including the following market information:
Global Anti-VEGF Medicine Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Anti-VEGF Medicine Market Sales, 2018-2023, 2024-2030, (K Units)
Global top five Anti-VEGF Medicine companies in 2022 (%)
The global Anti-VEGF Medicine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Single Target (Ranibizumab, etc.) Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Anti-VEGF Medicine include Faricimab, Bayer (Regeneron), Brolucizumab, Kanghong Pharmaceutical and Santen, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Anti-VEGF Medicine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-VEGF Medicine Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Anti-VEGF Medicine Market Segment Percentages, by Type, 2022 (%)
Single Target (Ranibizumab, etc.)
Multiple Targets (Aflibercept, Conbercept, etc.)
Global Anti-VEGF Medicine Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Anti-VEGF Medicine Market Segment Percentages, by Application, 2022 (%)
Hospital
Eye Clinic
Other
Global Anti-VEGF Medicine Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Anti-VEGF Medicine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anti-VEGF Medicine revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Anti-VEGF Medicine revenues share in global market, 2022 (%)
Key companies Anti-VEGF Medicine sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Anti-VEGF Medicine sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Faricimab
Bayer (Regeneron)
Brolucizumab
Kanghong Pharmaceutical
Santen
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-VEGF Medicine, market overview.
Chapter 2: Global Anti-VEGF Medicine market size in revenue and volume.
Chapter 3: Detailed analysis of Anti-VEGF Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-VEGF Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Anti-VEGF Medicine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Anti-VEGF Medicine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Anti-VEGF Medicine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Anti-VEGF Medicine Overall Market Size
2.1 Global Anti-VEGF Medicine Market Size: 2022 VS 2030
2.2 Global Anti-VEGF Medicine Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Anti-VEGF Medicine Sales: 2018-2030
3 Company Landscape
3.1 Top Anti-VEGF Medicine Players in Global Market
3.2 Top Global Anti-VEGF Medicine Companies Ranked by Revenue
3.3 Global Anti-VEGF Medicine Revenue by Companies
3.4 Global Anti-VEGF Medicine Sales by Companies
3.5 Global Anti-VEGF Medicine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Anti-VEGF Medicine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Anti-VEGF Medicine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Anti-VEGF Medicine Players in Global Market
3.8.1 List of Global Tier 1 Anti-VEGF Medicine Companies
3.8.2 List of Global Tier 2 and Tier 3 Anti-VEGF Medicine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Anti-VEGF Medicine Market Size Markets, 2022 & 2030
4.1.2 Single Target (Ranibizumab, etc.)
4.1.3 Multiple Targets (Aflibercept, Conbercept, etc.)
4.2 By Type - Global Anti-VEGF Medicine Revenue & Forecasts
4.2.1 By Type - Global Anti-VEGF Medicine Revenue, 2018-2023
4.2.2 By Type - Global Anti-VEGF Medicine Revenue, 2024-2030
4.2.3 By Type - Global Anti-VEGF Medicine Revenue Market Share, 2018-2030
4.3 By Type - Global Anti-VEGF Medicine Sales & Forecasts
4.3.1 By Type - Global Anti-VEGF Medicine Sales, 2018-2023
4.3.2 By Type - Global Anti-VEGF Medicine Sales, 2024-2030
4.3.3 By Type - Global Anti-VEGF Medicine Sales Market Share, 2018-2030
4.4 By Type - Global Anti-VEGF Medicine Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Anti-VEGF Medicine Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Eye Clinic
5.1.4 Other
5.2 By Application - Global Anti-VEGF Medicine Revenue & Forecasts
5.2.1 By Application - Global Anti-VEGF Medicine Revenue, 2018-2023
5.2.2 By Application - Global Anti-VEGF Medicine Revenue, 2024-2030
5.2.3 By Application - Global Anti-VEGF Medicine Revenue Market Share, 2018-2030
5.3 By Application - Global Anti-VEGF Medicine Sales & Forecasts
5.3.1 By Application - Global Anti-VEGF Medicine Sales, 2018-2023
5.3.2 By Application - Global Anti-VEGF Medicine Sales, 2024-2030
5.3.3 By Application - Global Anti-VEGF Medicine Sales Market Share, 2018-2030
5.4 By Application - Global Anti-VEGF Medicine Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Anti-VEGF Medicine Market Size, 2022 & 2030
6.2 By Region - Global Anti-VEGF Medicine Revenue & Forecasts
6.2.1 By Region - Global Anti-VEGF Medicine Revenue, 2018-2023
6.2.2 By Region - Global Anti-VEGF Medicine Revenue, 2024-2030
6.2.3 By Region - Global Anti-VEGF Medicine Revenue Market Share, 2018-2030
6.3 By Region - Global Anti-VEGF Medicine Sales & Forecasts
6.3.1 By Region - Global Anti-VEGF Medicine Sales, 2018-2023
6.3.2 By Region - Global Anti-VEGF Medicine Sales, 2024-2030
6.3.3 By Region - Global Anti-VEGF Medicine Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Anti-VEGF Medicine Revenue, 2018-2030
6.4.2 By Country - North America Anti-VEGF Medicine Sales, 2018-2030
6.4.3 US Anti-VEGF Medicine Market Size, 2018-2030
6.4.4 Canada Anti-VEGF Medicine Market Size, 2018-2030
6.4.5 Mexico Anti-VEGF Medicine Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Anti-VEGF Medicine Revenue, 2018-2030
6.5.2 By Country - Europe Anti-VEGF Medicine Sales, 2018-2030
6.5.3 Germany Anti-VEGF Medicine Market Size, 2018-2030
6.5.4 France Anti-VEGF Medicine Market Size, 2018-2030
6.5.5 U.K. Anti-VEGF Medicine Market Size, 2018-2030
6.5.6 Italy Anti-VEGF Medicine Market Size, 2018-2030
6.5.7 Russia Anti-VEGF Medicine Market Size, 2018-2030
6.5.8 Nordic Countries Anti-VEGF Medicine Market Size, 2018-2030
6.5.9 Benelux Anti-VEGF Medicine Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Anti-VEGF Medicine Revenue, 2018-2030
6.6.2 By Region - Asia Anti-VEGF Medicine Sales, 2018-2030
6.6.3 China Anti-VEGF Medicine Market Size, 2018-2030
6.6.4 Japan Anti-VEGF Medicine Market Size, 2018-2030
6.6.5 South Korea Anti-VEGF Medicine Market Size, 2018-2030
6.6.6 Southeast Asia Anti-VEGF Medicine Market Size, 2018-2030
6.6.7 India Anti-VEGF Medicine Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Anti-VEGF Medicine Revenue, 2018-2030
6.7.2 By Country - South America Anti-VEGF Medicine Sales, 2018-2030
6.7.3 Brazil Anti-VEGF Medicine Market Size, 2018-2030
6.7.4 Argentina Anti-VEGF Medicine Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Anti-VEGF Medicine Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Anti-VEGF Medicine Sales, 2018-2030
6.8.3 Turkey Anti-VEGF Medicine Market Size, 2018-2030
6.8.4 Israel Anti-VEGF Medicine Market Size, 2018-2030
6.8.5 Saudi Arabia Anti-VEGF Medicine Market Size, 2018-2030
6.8.6 UAE Anti-VEGF Medicine Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 Faricimab
7.1.1 Faricimab Company Summary
7.1.2 Faricimab Business Overview
7.1.3 Faricimab Anti-VEGF Medicine Major Product Offerings
7.1.4 Faricimab Anti-VEGF Medicine Sales and Revenue in Global (2018-2023)
7.1.5 Faricimab Key News & Latest Developments
7.2 Bayer (Regeneron)
7.2.1 Bayer (Regeneron) Company Summary
7.2.2 Bayer (Regeneron) Business Overview
7.2.3 Bayer (Regeneron) Anti-VEGF Medicine Major Product Offerings
7.2.4 Bayer (Regeneron) Anti-VEGF Medicine Sales and Revenue in Global (2018-2023)
7.2.5 Bayer (Regeneron) Key News & Latest Developments
7.3 Brolucizumab
7.3.1 Brolucizumab Company Summary
7.3.2 Brolucizumab Business Overview
7.3.3 Brolucizumab Anti-VEGF Medicine Major Product Offerings
7.3.4 Brolucizumab Anti-VEGF Medicine Sales and Revenue in Global (2018-2023)
7.3.5 Brolucizumab Key News & Latest Developments
7.4 Kanghong Pharmaceutical
7.4.1 Kanghong Pharmaceutical Company Summary
7.4.2 Kanghong Pharmaceutical Business Overview
7.4.3 Kanghong Pharmaceutical Anti-VEGF Medicine Major Product Offerings
7.4.4 Kanghong Pharmaceutical Anti-VEGF Medicine Sales and Revenue in Global (2018-2023)
7.4.5 Kanghong Pharmaceutical Key News & Latest Developments
7.5 Santen
7.5.1 Santen Company Summary
7.5.2 Santen Business Overview
7.5.3 Santen Anti-VEGF Medicine Major Product Offerings
7.5.4 Santen Anti-VEGF Medicine Sales and Revenue in Global (2018-2023)
7.5.5 Santen Key News & Latest Developments
8 Global Anti-VEGF Medicine Production Capacity, Analysis
8.1 Global Anti-VEGF Medicine Production Capacity, 2018-2030
8.2 Anti-VEGF Medicine Production Capacity of Key Manufacturers in Global Market
8.3 Global Anti-VEGF Medicine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Anti-VEGF Medicine Supply Chain Analysis
10.1 Anti-VEGF Medicine Industry Value Chain
10.2 Anti-VEGF Medicine Upstream Market
10.3 Anti-VEGF Medicine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Anti-VEGF Medicine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Anti-VEGF Medicine in Global Market
Table 2. Top Anti-VEGF Medicine Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Anti-VEGF Medicine Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Anti-VEGF Medicine Revenue Share by Companies, 2018-2023
Table 5. Global Anti-VEGF Medicine Sales by Companies, (K Units), 2018-2023
Table 6. Global Anti-VEGF Medicine Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Anti-VEGF Medicine Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Anti-VEGF Medicine Product Type
Table 9. List of Global Tier 1 Anti-VEGF Medicine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Anti-VEGF Medicine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Anti-VEGF Medicine Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Anti-VEGF Medicine Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Anti-VEGF Medicine Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Anti-VEGF Medicine Sales (K Units), 2018-2023
Table 15. By Type - Global Anti-VEGF Medicine Sales (K Units), 2024-2030
Table 16. By Application ? Global Anti-VEGF Medicine Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Anti-VEGF Medicine Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Anti-VEGF Medicine Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Anti-VEGF Medicine Sales (K Units), 2018-2023
Table 20. By Application - Global Anti-VEGF Medicine Sales (K Units), 2024-2030
Table 21. By Region ? Global Anti-VEGF Medicine Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Anti-VEGF Medicine Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Anti-VEGF Medicine Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Anti-VEGF Medicine Sales (K Units), 2018-2023
Table 25. By Region - Global Anti-VEGF Medicine Sales (K Units), 2024-2030
Table 26. By Country - North America Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Anti-VEGF Medicine Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Anti-VEGF Medicine Sales, (K Units), 2018-2023
Table 29. By Country - North America Anti-VEGF Medicine Sales, (K Units), 2024-2030
Table 30. By Country - Europe Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Anti-VEGF Medicine Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Anti-VEGF Medicine Sales, (K Units), 2018-2023
Table 33. By Country - Europe Anti-VEGF Medicine Sales, (K Units), 2024-2030
Table 34. By Region - Asia Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Anti-VEGF Medicine Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Anti-VEGF Medicine Sales, (K Units), 2018-2023
Table 37. By Region - Asia Anti-VEGF Medicine Sales, (K Units), 2024-2030
Table 38. By Country - South America Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Anti-VEGF Medicine Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Anti-VEGF Medicine Sales, (K Units), 2018-2023
Table 41. By Country - South America Anti-VEGF Medicine Sales, (K Units), 2024-2030
Table 42. By Country - Middle East & Africa Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Anti-VEGF Medicine Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Anti-VEGF Medicine Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Anti-VEGF Medicine Sales, (K Units), 2024-2030
Table 46. Faricimab Company Summary
Table 47. Faricimab Anti-VEGF Medicine Product Offerings
Table 48. Faricimab Anti-VEGF Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Faricimab Key News & Latest Developments
Table 50. Bayer (Regeneron) Company Summary
Table 51. Bayer (Regeneron) Anti-VEGF Medicine Product Offerings
Table 52. Bayer (Regeneron) Anti-VEGF Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Bayer (Regeneron) Key News & Latest Developments
Table 54. Brolucizumab Company Summary
Table 55. Brolucizumab Anti-VEGF Medicine Product Offerings
Table 56. Brolucizumab Anti-VEGF Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Brolucizumab Key News & Latest Developments
Table 58. Kanghong Pharmaceutical Company Summary
Table 59. Kanghong Pharmaceutical Anti-VEGF Medicine Product Offerings
Table 60. Kanghong Pharmaceutical Anti-VEGF Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Kanghong Pharmaceutical Key News & Latest Developments
Table 62. Santen Company Summary
Table 63. Santen Anti-VEGF Medicine Product Offerings
Table 64. Santen Anti-VEGF Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Santen Key News & Latest Developments
Table 66. Anti-VEGF Medicine Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 67. Global Anti-VEGF Medicine Capacity Market Share of Key Manufacturers, 2021-2023
Table 68. Global Anti-VEGF Medicine Production by Region, 2018-2023 (K Units)
Table 69. Global Anti-VEGF Medicine Production by Region, 2024-2030 (K Units)
Table 70. Anti-VEGF Medicine Market Opportunities & Trends in Global Market
Table 71. Anti-VEGF Medicine Market Drivers in Global Market
Table 72. Anti-VEGF Medicine Market Restraints in Global Market
Table 73. Anti-VEGF Medicine Raw Materials
Table 74. Anti-VEGF Medicine Raw Materials Suppliers in Global Market
Table 75. Typical Anti-VEGF Medicine Downstream
Table 76. Anti-VEGF Medicine Downstream Clients in Global Market
Table 77. Anti-VEGF Medicine Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Anti-VEGF Medicine Segment by Type in 2022
Figure 2. Anti-VEGF Medicine Segment by Application in 2022
Figure 3. Global Anti-VEGF Medicine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Anti-VEGF Medicine Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Anti-VEGF Medicine Revenue, 2018-2030 (US$, Mn)
Figure 7. Anti-VEGF Medicine Sales in Global Market: 2018-2030 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Anti-VEGF Medicine Revenue in 2022
Figure 9. By Type - Global Anti-VEGF Medicine Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Anti-VEGF Medicine Revenue Market Share, 2018-2030
Figure 11. By Type - Global Anti-VEGF Medicine Sales Market Share, 2018-2030
Figure 12. By Type - Global Anti-VEGF Medicine Price (US$/Unit), 2018-2030
Figure 13. By Application - Global Anti-VEGF Medicine Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Anti-VEGF Medicine Revenue Market Share, 2018-2030
Figure 15. By Application - Global Anti-VEGF Medicine Sales Market Share, 2018-2030
Figure 16. By Application - Global Anti-VEGF Medicine Price (US$/Unit), 2018-2030
Figure 17. By Region - Global Anti-VEGF Medicine Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Anti-VEGF Medicine Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Anti-VEGF Medicine Revenue Market Share, 2018-2030
Figure 20. By Region - Global Anti-VEGF Medicine Sales Market Share, 2018-2030
Figure 21. By Country - North America Anti-VEGF Medicine Revenue Market Share, 2018-2030
Figure 22. By Country - North America Anti-VEGF Medicine Sales Market Share, 2018-2030
Figure 23. US Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Anti-VEGF Medicine Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Anti-VEGF Medicine Sales Market Share, 2018-2030
Figure 28. Germany Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 29. France Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Anti-VEGF Medicine Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Anti-VEGF Medicine Sales Market Share, 2018-2030
Figure 37. China Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 41. India Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Anti-VEGF Medicine Revenue Market Share, 2018-2030
Figure 43. By Country - South America Anti-VEGF Medicine Sales Market Share, 2018-2030
Figure 44. Brazil Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Anti-VEGF Medicine Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Anti-VEGF Medicine Sales Market Share, 2018-2030
Figure 48. Turkey Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Anti-VEGF Medicine Revenue, (US$, Mn), 2018-2030
Figure 52. Global Anti-VEGF Medicine Production Capacity (K Units), 2018-2030
Figure 53. The Percentage of Production Anti-VEGF Medicine by Region, 2022 VS 2030
Figure 54. Anti-VEGF Medicine Industry Value Chain
Figure 55. Marketing Channels
